Sun Pharma reports Q4 & full year results for FY26
Mumbai, May 22, 2026: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) reported financials for the fourth quarter ending March 31st, 2026.
Highlights of Q4FY26 consolidated financials
- Sales at 145,598 million, a growth of 13.6%
- Global Innovative Medicines** sales at US$ 354
- Global Innovative Medicines sales up 1%, accounting for 22.2% of sales.
- EBITDA was 39,542 million, up 6.4%. EBITDA margin was 27.1%.
- Net profit was 27,140 million, up 26.2%
- R&D investment was 9,757 million at 6.7% of sales
Highlights of FY26 consolidated financials
- Sales at 582,201 million, a growth of 11.9%
- Global Innovative Medicines** sales at US$ 1,420 million
- Global Innovative Medicines sales up 4%, accounting for 20.7% of sales, both Ex-milestone.
- EBITDA was 177,314 million, up 16.1%. EBITDA margin was 30.3%.
- Net profit was 114,794 million, up 5.0%
- R&D investment was 35,540 million at 6.1% of sales
*Growth measured vs same period last financial year/ ** “Specialty” business renamed as “Innovative Medicines”
These results were taken on record by the Board of Directors at a meeting held today. The Board has proposed a final dividend of Rs. 5.00 per share for the year FY26. This is in addition to the interim dividend of Rs. 11.00 per share paid in FY26, taking the total dividend for FY26 to Rs. 16.00 per share, same as FY25.
Kirti Ganorkar, Managing Director of the Company, said, “Our full-year performance reflects several significant achievements. Sun’s 0.3 percentage point gain in the India market is our highest gain since the Ranbaxy acquisition. Our U.S. Innovative Medicines business has surpassed USD 1 billion in revenues, while Ex-US Innovative Medicines continues to demonstrate strong growth momentum. The recently announced Organon acquisition is expected to further accelerate Sun’s transformation into a leading global pharmaceutical company.”
India Formulations
Formulation sales in India were Rs. 48,359 million, registering a growth of 14.8%. India Formulation sales accounted for 33.2% of total consolidated sales. For the full year FY26, sales were Rs. 192,904 million, growing 14%.
Sun Pharma continues to be India’s No. 1 Pharma Company. Sun’s market share increased from 8.1% to 8.4%, as per the Pharmarack MAT Mar-2026 report. As per SMSRC (Nov-Feb 2026) report, Sun Pharma enjoys No.1 ranking by prescriptions in 11 different doctor categories. The company launched 11 new products during the quarter and 37 products in the full year.
US Formulations
Formulation sales in the US were US$ 459 million, lower by 1.1%. Innovative Medicines continued to grow offsetting the decline in generics business. US sales accounted for approximately 28.8% of total consolidated sales. For the full year FY26, sales were US$ 1,904 million.
Emerging Markets (EM) Formulations
Emerging Markets formulations sales were US$ 306 million, up by 17.4% and accounted for 19.2% of total consolidated sales. For the full year FY26, sales were US$ 1,265 million, growing 13.6%.
Rest of World (ROW) Formulations
Formulation sales in Rest of World markets were US$ 220 million, up by 10% and accounted for 13.8% of total consolidated sales. For the full year FY26, sales were US$ 969 million, up 14.4%.
Innovative Medicines
Global Innovative Medicines sales were US$ 354 million for Q4FY26, up 20.1% and accounted for 22.2% of sales. For the full year FY26, sales were US$ 1,420 million, up 16.8%.
Active Pharmaceutical Ingredients (API)
Our API portfolio supports our formulation business and API customers across geographies. External sales of API were Rs. 6,739 million, up 26.4%. For the full year FY26, API sales were Rs. 21,853 million, up 2.6%.
R&D Update
Sun Pharma’s R&D efforts span across both innovative and generic businesses and the company continues to invest in building the pipeline for various markets. Sun’s innovative R&D pipeline includes five novel entities in clinical stage. Sun has a comprehensive product offering in the US market consisting of approved ANDAs for 552 products while filings for 122 ANDAs await US FDA approval, including 28 tentative approvals. During the quarter, 7 ANDAs were filed, and approval received for 2 ANDAs.
Sun’s portfolio includes 57 approved NDAs while 13 NDAs await US FDA approval.
